KOSDAQBiotech & Pharma468530

Proteina

₩53,300▲ 7.03%2026-11-18 close
Market Cap
₩591.9B
Turnover
₩11.4B
Volume
210K
Shares out.
11.1M
PER
—
PBR
24.4×
EPS
-₩1,135
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

AI antibody platform in preclinical validation amid losses

Revenue rose 28.3% in 2025, but the operating loss widened and has continued for five straight quarters through Q3 2026, so preclinical pipeline data and licensing talks are the next checkpoints.

  1. 1

    Revenue reached KRW 2.95 billion in 2025, up 28.3% year on year, while the operating loss widened to KRW 11.4 billion.

  2. 2

    Q3 2026 revenue was KRW 187 million, down 67.8% from a year earlier, and the operating loss was KRW 4.05 billion.

  3. 3

    PRT-101 for osteoarthritis and PRT1309 for obesity and diabetes are both preclinical, with new data shown at 2026 conferences.

  4. 4

    A KRW 1.17 billion service contract signed in September 2025 and a national R&D project selected in November 2025 expand the revenue base.

  5. 5

    The debt ratio was 11.9% at end-2025, but operating cash flow was -KRW 8.07 billion in 2025.

02

Business structure

Proteina is an AI drug discovery company that identifies and designs drug candidates based on protein-protein interaction (PPI) data. Its revenue base is a PPI analysis solution supplied to pharmaceutical companies as a service, built on the SPID platform with its PPI PathFinder and PPI Landscape tools.

The company says its technology covers the full cycle of drug development, and a 2025 first-half report cited demand for biomarker analysis in translational research as a growth driver.

In September 2025 it disclosed a service supply contract with a US multinational pharmaceutical company worth KRW 1.17 billion, running through December 31, 2028. According to the same report, PPI Landscape, a newer revenue line, brought in about KRW 100 million in the first half of 2025, roughly 6.4% of revenue.

Customers are described as growing in number across domestic and overseas pharmaceutical companies. Its own pipeline comprises PRT-101, an osteoarthritis candidate that targets the SOX9 protein, and PRT1309, an obesity and diabetes candidate based on GIPR antagonism; both are at the preclinical stage.

In November 2025 it disclosed selection as the lead research institution for a national project on AI-assisted antibody biobetter development, with government funding of KRW 30.3 billion and private funding of KRW 13.6 billion.

The two amounts sum to KRW 43.9 billion, which differs from the KRW 47 billion scale in the report.

In competition, Proteina focuses on antibody design and AI drug discovery platforms, and its revenue model differs from that of Alteogen, which relies on formulation technology licensing, and Samsung Biologics, which is a contract manufacturer.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩600M-₩2.9B−506.4%
2025Q4₩300M-₩4.4B−1295.4%
2026Q1₩200M-₩4.7B−2795.5%
2026Q2₩300M-₩4B−1132.6%
2026Q3₩200M-₩4B−2161.1%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2024₩2.3B-₩9.1B-₩5.7B−396.5%−36.4%14.0%
2025₩3B-₩11.4B-₩9B−385.2%−31.8%11.9%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

Annual results show revenue growth alongside a larger loss. Revenue rose from KRW 2.3 billion in 2024 to KRW 2.95 billion in 2025, up 28.3%, while the operating loss widened from KRW 9.12 billion to KRW 11.4 billion.

The operating margin moved from -396.5% in 2024 to -385.2% in 2025, a slight narrowing of the loss relative to sales as revenue growth offset part of the wider loss. The net loss attributable to controlling shareholders grew from KRW 5.73 billion in 2024 to KRW 9.01 billion in 2025, two straight years of losses.

The net loss including noncontrolling interests followed the same path, from KRW 5.73 billion to KRW 9.01 billion.

The net loss was smaller than the operating loss in both years, which suggests non-operating items offset part of the operating loss; the breakdown should be checked in the income statement of the annual report.

An early 2025 report attributed the 2024 operating loss widening partly to government-funded research costs being booked as expenses rather than recognized against revenue. Operating cash flow went from -KRW 6.08 billion in 2024 to -KRW 8.07 billion in 2025.

On a quarterly basis, revenue fell from KRW 582 million in Q3 2025 to KRW 343 million in Q4 2025 (down 41.0% quarter on quarter) and to KRW 169 million in Q1 2026 (down 50.9%), then rebounded to KRW 349 million in Q2 2026 (up 107.2%) before dropping to KRW 187 million in Q3 2026 (down 46.4% quarter on quarter and down 67.8% year on year).

The operating loss widened from KRW 2.95 billion in Q3 2025 to KRW 4.45 billion in Q4 2025 and KRW 4.71 billion in Q1 2026, narrowed to KRW 3.96 billion in Q2 2026, and widened again to KRW 4.05 billion in Q3 2026. The company has posted operating losses for five consecutive quarters from Q3 2025 through Q3 2026.

The net loss attributable to controlling shareholders was KRW 2.96 billion in Q3 2026, and the last four quarters total KRW 12.4 billion. Quarterly revenue appears to move with the timing of contract recognition, while fixed-type research costs remain, so the loss structure is unlikely to change quickly.

05

Industry analysis

Demand from downstream markets has two sides. The first is demand for biobetters, which are improved versions of existing antibody drugs in efficacy and ease of administration, and Proteina's national project and antibody design work sit in this area.

The second is demand for biomarker analysis used in translational research by pharmaceutical companies, which a 2025 first-half report cited as a growth driver.

A company profile site projected the global proteomics market at KRW 116 trillion by 2030, but this is an external forecast and is not directly linked to the company's revenue. In osteoarthritis, no disease-modifying drug (DMOAD) has been approved globally, which defines the position of PRT-101.

The leading phase 3 candidate reportedly showed a partial effect in slowing joint space loss in the knee, but reports noted limited pain relief and low efficacy in severe patients.

In obesity and diabetes, the mechanism focus is widening from agonists toward inhibitory approaches, and Amgen's MariTide is in clinical development in the same class, according to a May 2026 report. Because PRT1309 is a GIPR antagonist entering this competitive class, preclinical differentiation is a key variable.

Competitive positioning has two axes. The combination of PPI big data and AI design is the differentiator, but the company has no clinical entry yet.

Its revenue scale is small within the sector, and its business structure differs from domestic listed biopharma companies whose earnings centre on contract manufacturing or technology licensing.

06

Outlook

The company has set a target of returning to profit in 2027. This target was presented in a November 2025 report and can be tested against 2027 results.

A December 2025 report from Shinyoung Securities described the company's goal of developing 10 AI-designed antibody drug candidates by the end of 2027, filing an IND application for one, and entering preclinical stage for three.

For PRT1309, the company said in May 2026 that it targets validation in a primate model by year-end 2026 and plans to pursue an IND filing within 2027. Selection for an oral presentation at ADA 2026 may serve as an early academic validation signal.

PRT-101 presented early preclinical data at OARSI 2026 in April 2026 and then direct comparative preclinical results against the phase 3 candidate lorecivivint at EULAR 2026 in June 2026. The company said it will move forward with follow-on clinical development and licensing discussions.

At BIO USA 2026 in June 2026, the company said it planned partnering meetings with global pharmaceutical companies. The national project aims at an IND application for the final candidate, and government and private funding are expected to continue over the project period.

At the March 2026 shareholder meeting, the company added drug licensing out and in, and AI-based drug discovery solutions, to its articles of incorporation. The clinical sample analysis contract running through December 31, 2028 provides some visibility on revenue.

The next checkpoint is the annual operating loss in the 2026 annual report and progress toward the 2027 profitability target.

07

Valuation

PER
—
PBR
24.4×
ROE
-48.3%
EPS
-₩1,135
BPS
₩2,050
Dividend per share
₩0

Because the company has posted net losses over the last four quarters, a price-to-earnings multiple cannot be calculated, and comparisons on earnings-based multiples do not apply.

On a book-value basis, the price-to-book ratio sits in a range with a large premium over net assets, which suggests the market is placing value on the pipeline and platform growth rather than current earnings.

Total equity was KRW 28.4 billion at end-2025 and total liabilities were KRW 3.38 billion, so the financial burden is small, but if operating cash outflows continue, the capacity of equity will be gradually consumed. The company pays no dividend, so comparisons on dividend yield do not apply.

Against listed peers in the same sector, direct comparison on earnings-based multiples is difficult, and the basis for valuation shifts with pipeline data and whether licensing deals are concluded.

Because the operating losses have persisted, the trend of losses and changes in equity matter more than multiples for interpreting the valuation.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Preclinical data accumulating

PRT-101 presented early preclinical data at OARSI 2026 in April 2026, then direct comparison results against the phase 3 candidate lorecivivint at EULAR 2026 in June. PRT1309 was selected for an oral presentation at ADA 2026, an opportunity reported to go to fewer than 5% of submitted studies. As conference validation builds up, the basis for licensing talks also grows.

Wider revenue sources and national project

A clinical sample analysis contract disclosed in September 2025 is worth KRW 1.17 billion and runs through December 31, 2028. In November 2025 the company was selected as lead research institution for a national project with reported government funding of KRW 30.3 billion and private funding of KRW 13.6 billion. With PPI Landscape revenue newly added, revenue sources are extending beyond PPI analysis services.

Light balance sheet burden

Total liabilities were KRW 3.38 billion at end-2025, and the debt ratio fell to 11.9% from 14.0% in 2024. Total equity of KRW 28.4 billion is entirely attributable to controlling shareholders, which keeps the capital structure simple.

The company said proceeds from its July 2025 KOSDAQ listing would go toward expanding its PPI big data platform and global collaborations.

09

Bear factors

Persistent losses and cash outflow

Operating losses have continued for five consecutive quarters through Q3 2026, and the net loss attributable to controlling shareholders over the last four quarters totals KRW 12.4 billion. Operating cash flow was -KRW 8.07 billion in 2025, a larger outflow than in 2024. With an operating margin of -385.2%, revenue has not yet caught up with the cost base.

Volatile quarterly revenue

Q3 2026 revenue was KRW 187 million, down 67.8% from a year earlier. After KRW 582 million in Q3 2025, quarterly revenue moved between KRW 169 million in Q1 2026 and KRW 349 million in Q2 2026. Because contract revenue appears to land at specific points in time, quarterly results are relatively hard to predict.

Clinical proof still outstanding

PRT-101 and PRT1309 are both preclinical, and the IND filing for PRT1309 is targeted within 2027. A Thinkpool report pointed out that the next task is to show, in the clinic, that AI-designed drugs actually work. Conference presentations and comparative data do not guarantee clinical success, so development risk remains.

10

Risk factors

Development timeline and clinical entry

Both pipeline assets are preclinical, so the timing of IND filings and clinical entry could slip. The targets are company-stated and could change depending on primate model validation results. Conference data may not translate into clinical results, which is also a risk factor.

Revenue concentration and accounting treatment

Accounting for government-funded research costs as expenses rather than against revenue was reported to have contributed to the wider 2024 operating loss.

Because revenue is tied to specific contracts and projects, a single contract delay or a change in revenue recognition timing could shift quarterly results significantly.

Share count increase and shareholder structure

Stock options were exercised on April 27, 2026, with director Choi Byungsan acquiring 3,343 shares, and executive Lee Hong-won's holding rose by 68,000 shares from November 27, 2025, according to disclosures. The largest shareholder and related parties held 22.81% as of December 2025. Continued option exercises would add to the share count and act as a dilution factor.

11

What to watch next

  1. Late December 2026

    Primate model validation results for PRT1309, a target the company set for year-end 2026. The result would serve as the basis for pursuing an IND filing in 2027.

  2. Late March 2027

    Deadline for the 2026 annual report. Annual revenue, operating loss, Q4 2026 results and cost breakdown will be confirmed in the periodic filing.

  3. Mid-2027

    Whether the IND filing for PRT1309 proceeds, showing if preclinical data advance to the regulatory submission stage.

  4. 2027 (company target year)

    Progress toward the profitability target. The quarterly operating loss trend in 2027 will indicate whether the target is being met.

12

Overall view

Proteina is an AI antibody design platform company built on PPI data, and its revenue base is widening through service contracts and a national project.

Revenue rose 28.3% to KRW 2.95 billion in 2025, but the operating loss widened to KRW 11.4 billion, and operating losses have continued for five straight quarters through Q3 2026. Q3 2026 revenue of KRW 187 million was down 67.8% year on year, so quarterly revenue remains volatile.

Its own pipeline assets, PRT-101 and PRT1309, presented preclinical data at 2026 conferences and have entered the validation stage, but clinical entry remains a target for an IND filing within 2027.

On the financial side, the debt ratio was 11.9% at end-2025, which means a light debt burden, but continued operating cash outflows make the pace at which equity is used up a key point to monitor.

Bullish factors are conference validation, a wider revenue base from contracts and a national project, and low debt; bearish factors are prolonged losses, quarterly revenue swings, and development risk at the preclinical stage.

Because no earnings-based multiple can be calculated, pipeline evaluation and the loss trend are central to interpretation. The next checkpoints are the PRT1309 primate validation result at year-end 2026, the annual operating loss in the 2026 annual report, and progress toward the 2027 profitability target.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 15 more articles and sources
  1. comp.fnguide.com
  2. comp.fnguide.com
  3. m.thinkpool.com
  4. m.thinkpool.com
  5. sedaily.com
  6. news.nate.com
  7. scoreport.kr
  8. m.finance.daum.net
  9. news.nate.com
  10. news.nate.com
  11. news.nate.com
  12. news.nate.com
  13. news.nate.com
  14. m.news.nate.com
  15. view.asiae.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis